It is mainly used for the treatment of the onset of diet and exercise alone control ineffective of adulthood, and no ketosis tendency of light, moderate the type II diabetes. It also can improve diabetic retinopathy and metabolic disorders, vascular function. It can be used with biguanide oral...
Gliclazide (GLZ) BCS class II drug, is an oral antihyperglycemic agent used for the treatment of non- insulin-dependent diabetes mellitus However, low aqueous solubility and poor dissolution of this molecule, delays its rate of absorption and finally the onset of action. Solid dispersion has been...
It is mainly used for the treatment of the onset of diet and exercise alone control ineffective of adulthood, and no ketosis tendency of light, moderate the type II diabetes. It also can improve diabetic retinopathy and metabolic disorders, vascular function. It can be used with biguanide oral...
Gliclazide is mainly used for mild and moderate type II diabetes mellitus with adult-onset where diet and exercise control alone are ineffective and without a tendency to ketosis, and also improves fundus lesions and metabolic and vascular dysfunctions in diabetic patients. ...
Poor aqueous solubility of BCS class II oral antidiabetics produces variable bioavailability, high fasted/fed state variation, retarded onset of therapeutic action, irreproducible therapeutic response and need a large amount of oral dose for the administration of hypoglycemic drugs7,8,9. Gliclazide, a...
The optimized film formulation (FG4) showed excellent stability over 45 days when stored at 40掳C /60% RH. The pharmacodynamic study in animal models (rats) proved that fast dissolving films of gliclazide produced a faster onset of action compared to that of conventional formulation....
Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.doi:10.1016/0002-9343(91)90416-UIn 10 obese, new-onset non-insulin-dependent diabetes mellitus (NIDDM) patients (...
affecting the onset of action and intensity of pharmacological effects in vivo [2,3]. A second-generation sulfonylureas, Gliclazide (GCZ), [1-(3-azabicyclo (3, 3,0) oct-3-yl)-3-(p-tolylsulfonyl) urea] has transformed the treatment of type 2 diabetes/noninsulin dependent diabetes mellitus...